Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devalingam Mahalingam

Showing results (21-30 of 103) with videos related to

Pageof 11
Sort By:
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
BMC Cancer|July 10, 2015
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancerDevalingam Mahalingam, Sukeshi Patel, Gerard Nuovo, et al.
Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2014
Predicting success in regulatory approval from Phase I resultsLaeeq Malik, Alex Mejia, Helen Parsons, et al.
Clinical Genitourinary Cancer|March 4, 2014
Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trialsLaeeq Malik, Helen Parsons, Devalingam Mahalingam, et al.
Expert Opinion on Emerging Drugs|May 27, 2009
Emerging drugs in the treatment of pancreatic cancerDevalingam Mahalingam, Kevin R Kelly, Ronan T Swords, et al.
Oncotarget|July 28, 2016
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancerSukeshi Patel, Vincent Hurez, Steffan T Nawrocki, et al.
Cancers|August 28, 2025
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational BurdenImran Nizamuddin, Tarik Demir, Katrina Dobinda, et al.
Current Drug Targets|July 23, 2011
Targeting aurora kinases in cancer treatmentKevin R Kelly, Jeffrey Ecsedy, Devalingam Mahalingam, et al.
Journal of Gastrointestinal Oncology|April 29, 2014
Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trialsSukeshi R Patel, Anand B Karnad, Norma S Ketchum, et al.
Pageof 11

Showing results (21-30 of 103) with videos related to

Sort By:
Pageof 11
Current Drug Targets|October 29, 2009
Targeting sarcomas: novel biological agents and future perspectivesDevalingam Mahalingam, Alain Mita, Kamalesh Sankhala, et al.
BMC Cancer|July 10, 2015
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancerDevalingam Mahalingam, Sukeshi Patel, Gerard Nuovo, et al.
Current Drug Targets|July 23, 2011
The Pim kinases: new targets for drug developmentRonan Swords, Kevin Kelly, Jennifer Carew, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2014
Predicting success in regulatory approval from Phase I resultsLaeeq Malik, Alex Mejia, Helen Parsons, et al.
Clinical Genitourinary Cancer|March 4, 2014
Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trialsLaeeq Malik, Helen Parsons, Devalingam Mahalingam, et al.
Expert Opinion on Emerging Drugs|May 27, 2009
Emerging drugs in the treatment of pancreatic cancerDevalingam Mahalingam, Kevin R Kelly, Ronan T Swords, et al.
Oncotarget|July 28, 2016
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancerSukeshi Patel, Vincent Hurez, Steffan T Nawrocki, et al.
Cancers|August 28, 2025
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational BurdenImran Nizamuddin, Tarik Demir, Katrina Dobinda, et al.
Current Drug Targets|July 23, 2011
Targeting aurora kinases in cancer treatmentKevin R Kelly, Jeffrey Ecsedy, Devalingam Mahalingam, et al.
Journal of Gastrointestinal Oncology|April 29, 2014
Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trialsSukeshi R Patel, Anand B Karnad, Norma S Ketchum, et al.
Pageof 11